

# Charlotte Hedskog

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7426254/publications.pdf>

Version: 2024-02-01

14  
papers

754  
citations

1039880

9  
h-index

1058333

14  
g-index

14  
all docs

14  
docs citations

14  
times ranked

1300  
citing authors

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 1  | Real-world safety and effectiveness of ledipasvir/sofosbuvir for the treatment of chronic hepatitis C virus genotype 1 in Japan. <i>Journal of Viral Hepatitis</i> , 2021, 28, 129-141.                    | 1.0 | 5         |
| 2  | Prevalence of resistance-associated substitutions and phylogenetic analysis of hepatitis C virus infection in Russia. <i>International Journal of Infectious Diseases</i> , 2021, 113, 36-42.              | 1.5 | 5         |
| 3  | Hepatitis C virus genotype 1 and 2 recombinant genomes and the phylogeographic history of the 2k/1b lineage. <i>Virus Evolution</i> , 2019, 5, vez041.   | 2.2 | 5         |
| 4  | HIV co-infection is associated with increased transmission risk in patients with chronic hepatitis C virus. <i>Journal of Viral Hepatitis</i> , 2019, 26, 1351-1354.                                       | 1.0 | 3         |
| 5  | Identification of 19 Novel Hepatitis C Virus Subtypes—Further Expanding HCV Classification. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz076.   | 0.4 | 72        |
| 6  | Long-Term Persistence of HCV NS5A Resistance-Associated Substitutions after Treatment with the HCV NS5A Inhibitor, Ledipasvir, without Sofosbuvir. <i>Antiviral Therapy</i> , 2018, 23, 229-238.           | 0.6 | 57        |
| 7  | Resistance analysis in patients with genotype 1 HCV infection treated with sofosbuvir/velpatasvir in the phase III studies. <i>Journal of Hepatology</i> , 2018, 68, 895-903.                              | 1.8 | 82        |
| 8  | Identification of a Novel Hepatitis C Virus Genotype From Punjab, India: Expanding Classification of Hepatitis C Virus Into 8 Genotypes. <i>Journal of Infectious Diseases</i> , 2018, 218, 1722-1729.     | 1.9 | 202       |
| 9  | HCV phylogenetic signature and prevalence of pretreatment NS5A and NS5B NI-Resistance associated substitutions in HCV-Infected patients in Mainland China. <i>Antiviral Research</i> , 2018, 158, 178-184. | 1.9 | 17        |
| 10 | Antiviral response and resistance analysis of treatment-naïve HCV infected patients receiving multiple doses of the NS3 protease inhibitor GS-9256. <i>Antiviral Research</i> , 2017, 140, 151-157.        | 1.9 | 5         |
| 11 | Global epidemiology of HCV subtypes and resistance-associated substitutions evaluated by sequencing-based subtype analyses. <i>Journal of Hepatology</i> , 2017, 67, 224-236.                              | 1.8 | 110       |
| 12 | L159F and V321A Sofosbuvir-Associated Hepatitis C Virus NS5B Substitutions. <i>Journal of Infectious Diseases</i> , 2016, 213, 1240-1247.  | 1.9 | 86        |
| 13 | Genotype- and Subtype-Independent Full-Genome Sequencing Assay for Hepatitis C Virus. <i>Journal of Clinical Microbiology</i> , 2015, 53, 2049-2059.   | 1.8 | 25        |
| 14 | Characterization of hepatitis C virus intergenotypic recombinant strains and associated virological response to sofosbuvir/ribavirin. <i>Hepatology</i> , 2015, 61, 471-480.                               | 3.6 | 80        |